Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression

[1]  M. Heppt,et al.  Distinct antibody clones detect PD-1 checkpoint expression and block PD-L1 interactions on live murine melanoma cells , 2022, Scientific Reports.

[2]  Zhangang Xiao,et al.  PD-L1 regulates cell proliferation and apoptosis in acute myeloid leukemia by activating PI3K-AKT signaling pathway , 2022, Scientific Reports.

[3]  Z. Ou,et al.  Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity , 2022, Scientific Reports.

[4]  Saša B. Jović,et al.  Prognostic impact of miR-34b/c DNA methylation, gene expression, and promoter polymorphism in HPV-negative oral squamous cell carcinomas , 2022, Scientific Reports.

[5]  M. Kowalska,et al.  Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product , 2022, Scientific Reports.

[6]  S. Zeinali,et al.  The role of miRNA-377 as a tumor suppressor in lung cancer by negative regulation of genes belonging to ErbB signaling pathway , 2021, Molecular Biology Reports.

[7]  Dong-Wan Kim,et al.  Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment , 2021, Scientific Reports.

[8]  B. Baradaran,et al.  A Systematic Review on the Therapeutic Potentiality of PD-L1-Inhibiting MicroRNAs for Triple-Negative Breast Cancer: Toward Single-Cell Sequencing-Guided Biomimetic Delivery , 2021, Genes.

[9]  B. Győrffy,et al.  Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer , 2021, Computational and structural biotechnology journal.

[10]  Jaclyn Sceneay,et al.  The future of immune checkpoint combinations with tumor-targeted small molecule drugs , 2021, Emerging topics in life sciences.

[11]  Jyothi U. Menon,et al.  Current State of Breast Cancer Diagnosis, Treatment, and Theranostics , 2021, Pharmaceutics.

[12]  Song Liu,et al.  Differential methylation and expression patterns of microRNAs in relation to breast cancer subtypes among American women of African and European ancestry , 2021, PloS one.

[13]  Anh Nguyen-Duc,et al.  Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study , 2021, Journal of the National Cancer Institute.

[14]  W. Zhan,et al.  LncRNA EWSAT1 Promotes Colorectal Cancer Progression Through Sponging miR-326 to Modulate FBXL20 Expression , 2021, OncoTargets and therapy.

[15]  Lei Wu,et al.  Berberine inhibited metastasis through miR-145/MMP16 axis in vitro , 2021, Journal of Ovarian Research.

[16]  T. Sørlie,et al.  Crosstalk between microRNA expression and DNA methylation drive the hormone-dependent phenotype of breast cancer , 2020, bioRxiv.

[17]  Lisheng Wang,et al.  Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer , 2020, Cancers.

[18]  M. Wei,et al.  MiR-145-5p suppresses the proliferation, migration and invasion of gastric cancer epithelial cells via the ANGPT2/NOD_LIKE_RECEPTOR axis , 2020, Cancer Cell International.

[19]  Ran Wei,et al.  Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective , 2020, Frontiers in Immunology.

[20]  Yuqing Xiong,et al.  PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer , 2020, Cell Death & Disease.

[21]  A. Avan,et al.  Role of regulatory miRNAs of the Wnt/ β-catenin signaling pathway in tumorigenesis of breast cancer. , 2020, Gene.

[22]  Y. Guan,et al.  miR-145-5p attenuates paclitaxel resistance and suppresses the progression in drug-resistant breast cancer cell lines. , 2020, Neoplasma.

[23]  P. Shen,et al.  miR-335 Acts as a Tumor Suppressor and Enhances Ionizing Radiation-Induced Tumor Regression by Targeting ROCK1 , 2020, Frontiers in Oncology.

[24]  Lianhong Li,et al.  PD-1/PD-L1 pathway: current researches in cancer. , 2020, American journal of cancer research.

[25]  B. Baradaran,et al.  PD‐1/PD‐L1‐dependent immune response in colorectal cancer , 2020, Journal of cellular physiology.

[26]  朱利安·保罗·汉史克,et al.  Decitabine , 2009, Reactions Weekly.

[27]  P. Dong,et al.  Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion , 2018, Front. Oncol..

[28]  N S El Saghir,et al.  4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)† , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Lucy M. De La Cruz,et al.  Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer , 2018, Annals of Surgical Oncology.

[30]  Shiang-Fu Huang,et al.  Differential microRNA expression in breast cancer with different onset age , 2018, PloS one.

[31]  Libin Guo,et al.  The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint , 2017, International journal of molecular sciences.

[32]  M. Kok,et al.  Targeting immune checkpoints in breast cancer: an update of early results , 2017, ESMO Open.

[33]  L. Busund,et al.  Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer , 2017, PloS one.

[34]  P. Krawczyk,et al.  New Dancing Couple: PD‐L1 and MicroRNA , 2017, Scandinavian journal of immunology.

[35]  N. Zhang,et al.  miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression. , 2017, International journal of oncology.

[36]  Valeria Vitelli,et al.  Integrative clustering reveals a novel split in the luminal A subtype of breast cancer with impact on outcome , 2017, Breast Cancer Research.

[37]  Qi Zhou,et al.  Knockdown of PD-L1 in Human Gastric Cancer Cells Inhibits Tumor Progression and Improves the Cytotoxic Sensitivity to CIK Therapy , 2017, Cellular Physiology and Biochemistry.

[38]  Meng-Lay Lin,et al.  The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1 , 2017, Oncotarget.

[39]  D. Dai,et al.  Up-regulation of CRKL by microRNA-335 methylation is associated with poor prognosis in gastric cancer , 2017, Cancer Cell International.

[40]  J. Davison,et al.  5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers , 2016, Journal of Immunotherapy for Cancer.

[41]  T. Sørlie,et al.  Molecular Features of Subtype-Specific Progression from Ductal Carcinoma In Situ to Invasive Breast Cancer. , 2016, Cell reports.

[42]  F. Marmé,et al.  Immunotherapy in Breast Cancer , 2016, Oncology Research and Treatment.

[43]  Daniel S. Chen,et al.  Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  Ping Wang,et al.  miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint , 2016, Nature Communications.

[45]  G. Calin,et al.  PDL1 Regulation by p53 via miR-34 , 2015, Journal of the National Cancer Institute.

[46]  T. Kunej,et al.  MicroRNA Silencing by DNA Methylation in Human Cancer: a Literature Analysis , 2015, Non-coding RNA.

[47]  Prahlad T. Ram,et al.  Integrated analysis reveals microRNA networks coordinately expressed with key proteins in breast cancer , 2015, Genome Medicine.

[48]  Heping Cheng,et al.  Methylation-associated silencing of MicroRNA-335 contributes tumor cell invasion and migration by interacting with RASA1 in gastric cancer. , 2014, American journal of cancer research.

[49]  W. Coleman,et al.  Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. , 2013, The American journal of pathology.

[50]  Hiromu Suzuki,et al.  DNA methylation and microRNA dysregulation in cancer , 2012, Molecular oncology.

[51]  Yimin Xiong,et al.  Identification of hsa-miR-335 as a Prognostic Signature in Gastric Cancer , 2012, PloS one.

[52]  Xiaodong Jin,et al.  Tumor microRNA-335 expression is associated with poor prognosis in human glioma , 2012, Medical Oncology.

[53]  L. Langman,et al.  The challenges of personalized medicine. , 2012, Clinical biochemistry.

[54]  A. Aigner.  MicroRNAs (miRNAs) in cancer invasion and metastasis: therapeutic approaches based on metastasis-related miRNAs , 2011, Journal of Molecular Medicine.

[55]  Lieping Chen,et al.  B7‐H1 expression on non‐B and non‐T cells promotes distinct effects on T‐ and B‐cell responses in autoimmune arthritis , 2010, European journal of immunology.

[56]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[57]  Robert A. Weinberg,et al.  A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .

[58]  L. Hansen,et al.  Methylation-sensitive high-resolution melting , 2012 .

[59]  S. Ropero,et al.  A microRNA DNA methylation signature for human cancer metastasis , 2008, Proceedings of the National Academy of Sciences.

[60]  Laura Mosca,et al.  An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma , 2008, BMC medical genomics.

[61]  W. Gerald,et al.  Endogenous human microRNAs that suppress breast cancer metastasis , 2008, Nature.

[62]  A. Qattan,et al.  The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors. , 2006, Neoplasia.

[63]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[64]  D. Tripathy,et al.  Oncogenes and tumor suppressor genes in breast cancer: potential diagnostic and therapeutic applications. , 2004, The oncologist.

[65]  G. Horgan,et al.  Relative expression software tool (REST©) for group-wise comparison and statistical analysis of relative expression results in real-time PCR , 2002 .

[66]  C. Conner.  Literature Analysis , 1981 .